+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020

  • ID: 5174756
  • Drug Pipelines
  • September 2020
  • Region: Global
  • 770 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • BlueRock Therapeutics
  • Educell doo
  • Immplacate
  • Magenta Therapeutics Inc
  • SCM lifescience Co Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2020, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 12, 38, 15, 3, 39, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively.

Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • BlueRock Therapeutics
  • Educell doo
  • Immplacate
  • Magenta Therapeutics Inc
  • SCM lifescience Co Ltd
Introduction

Graft Versus Host Disease (GVHD) - Overview

Graft Versus Host Disease (GVHD) - Therapeutics Development

Graft Versus Host Disease (GVHD) - Therapeutics Assessment

Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development

Graft Versus Host Disease (GVHD) - Drug Profiles

Graft Versus Host Disease (GVHD) - Dormant Projects

Graft Versus Host Disease (GVHD) - Discontinued Products

Graft Versus Host Disease (GVHD) - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by AltruBio Inc, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by ASC Therapeutics Inc, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by AstraZeneca Plc, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H2 2020
  • Graft Versus Host Disease (GVHD) - Pipeline by Autolus Therapeutics Plc, H2 2020
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2020
  • Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Adienne Pharma & Biotech
  • AltruBio Inc
  • Amgen Inc
  • AnaptysBio Inc
  • apceth Biopharma GmbH
  • ASC Therapeutics Inc
  • AstraZeneca Plc
  • Athersys Inc
  • Autolus Therapeutics Plc
  • Bellicum Pharmaceuticals Inc
  • Biocon Ltd
  • Biogen Inc
  • BioIncept LLC
  • BioTheryX Inc
  • BlueRock Therapeutics
  • Boryung ViGenCell Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Cellect Biotechnology Ltd
  • Cellective BioTherapy Inc
  • Cellix Bio Pvt Ltd
  • CheckPoint Immunology Inc
  • Clinigen Group Plc
  • CSL Ltd
  • CTI BioPharma Corp
  • Cytodyn Inc
  • Cytopeutics Pte Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Dualogics Corp
  • Educell doo
  • Eli Lilly and Co
  • enGene Inc
  • Enlivex Therapeutics Ltd
  • Evive Biotech
  • ExCellThera Inc
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Fujifilm Holdings Corp
  • Genentech USA Inc
  • GigaGen Inc
  • GlaxoSmithKline Plc
  • Glia LLC
  • Humanigen Inc
  • iCELL Biotechnology Co Ltd
  • Immplacate
  • Immune Modulation Inc
  • ImmuneTarget Inc
  • Imstem Biotechnology Inc
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • Jazz Pharmaceuticals Plc
  • JN Biosciences LLC
  • Kadmon Corp LLC
  • Kalytera Therapeutics Inc
  • Kamada Ltd
  • Kiniksa Pharmaceuticals Ltd
  • Kymab Ltd
  • LG Chem Ltd
  • MaaT Pharma
  • Machavert Pharmaceuticals LLC
  • Magenta Therapeutics Inc
  • Mallinckrodt Plc
  • Medexus Pharmaceuticals Inc
  • Medicenna Therapeutics Corp
  • Mediolanum farmaceutici SpA
  • Medsenic SAS
  • Mereo Biopharma Group Plc
  • Mesoblast Ltd
  • Millennium Pharmaceuticals Inc
  • MitoImmune Therapeutics Inc
  • NapaJen Pharma Inc
  • Neovii Pharmaceuticals AG
  • Nurix Therapeutics Inc
  • OncoImmune Inc
  • OSE Immunotherapeutics
  • Panorama Research Inc
  • Pfizer Inc
  • Platinum Biotech (Beijing) Co Ltd
  • Pluristem Therapeutics Inc
  • Precision Biosciences Inc
  • REGiMMUNE Corp
  • SCM lifescience Co Ltd
  • Seattle Genetics Inc
  • Secura Bio Inc
  • Seres Therapeutics Inc
  • Shenzhen Chipscreen Biosciences Co Ltd
  • STERO Biotechs Ltd
  • StingInn LLC
  • Suzhou Connect Biopharmaceuticals Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • Syndax Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TCF GmbH
  • TeraImmune Inc
  • TGV Laboratories Inc
  • United BioPharma Inc
  • Vault Pharma Inc
  • Visterra Inc
  • Xenikos BV
  • Xenothera SAS
  • XL-protein GmbH
Note: Product cover images may vary from those shown
Adroll
adroll